TY - JOUR T1 - Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 260 LP - 263 DO - 10.1183/09059180.00005913 VL - 23 IS - 132 AU - David Montani AU - Laurent Bertoletti AU - Marie-Camille Chaumais AU - Swanny Perrin AU - Dominique Fabre AU - Ari Chaouat AU - Xavier Jaïs AU - Gérald Simonneau AU - Marc Humbert Y1 - 2014/06/01 UR - http://err.ersjournals.com/content/23/132/260.abstract N2 - To the Editor:Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe delayed complication after pulmonary embolism. Known risk factors of CTEPH include acute pulmonary embolism, the degree of pulmonary arterial occlusion, pulmonary embolism recurrence, splenectomy, ventriculo-arterial shunts, infected pacemakers and blood group O [1, 2]. Symptomatic pulmonary embolism is found in almost three-quarters of patients with CTEPH [3]. Cyproterone acetate, a synthetic steroidal antiandrogen drug with additional progestogen and antigonadotropic properties, is a major risk factor of venous thromboembolic disease [4, 5]. We report the first case of severe CTEPH occurring in the context of cyproterone acetate long-term exposure.A 55-year-old female was referred to our centre (French referral centre for pulmonary hypertension) for pulmonary hypertension. She was a former smoker (30 pack-years) and her medical history included migraine, systemic hypertension and severe acne (treated with cyproterone acetate, 50 mg daily) between 1992 and 2010 associated with ethinylestradiol therapy. The patient had no past history of pulmonary embolism or deep vein thrombosis. No risk factors for CTEPH … ER -